Dr. Soon-Shiong affiliate

ImmunityBio is a vertically integrated biotechnology company focused on developing next-generation immunotherapies that bolster the immune system to defeat cancers and infectious diseases. The company's lead product, Anktiva (N-803), is an FDA-approved IL-15 superagonist complex designed to activate natural killer (NK) cells and T cells, specifically for BCG-unresponsive non-muscle invasive bladder cancer. ImmunityBio's broader pipeline utilizes a multi-modal approach, combining cytokines, cell therapies, and adenovirus-based vaccines to induce long-lasting immune memory. Led by billionaire founder Dr. Patrick Soon-Shiong, the company maintains extensive internal manufacturing capabilities to support its diverse clinical programs across oncology and infectious disease.